Lipocine Inc (LPCN) 7.33 $LPCN
Male Hypogonadism Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Mar 12, 9:32AM CDT
The report "Male Hypogonadism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Male Hypogonadism. Male hypogonadism is the inability of the testicles to produce testosterone, sperm or both. The symptoms of male hypogonadism includes weakness, muscle and joint aches, increased fat or obesity, enlarged, swollen or tender breasts, reduced facial, body and pubic hair, decreased bone density, bone fractures or osteoporosis, loss of height, sleep apnea, night sweats or hot flushes and fatigue. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/male-hypogon...eport.html .
MRK: 58.58 (+0.37), AUXL: 36.47 (-0.06), LPCN: 7.33 (-0.14), ATRS: 2.67 (-0.02), NVS: 101.68 (+1.81)
Lipocine misses by $0.07
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 8:15AM CDT
LPCN: 7.33 (-0.14)
Lipocine Announces Financial and Operational Results for the Full Year 2014
GlobeNewswire - Wed Mar 11, 8:00AM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2014, as well as recent operational highlights.
LPCN: 7.33 (-0.14)
FDA imposes limits on testosterone drugs and labeling changes to warn of potential heart risks
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 7:23AM CST
ENDP: 92.37 (+0.89), AUXL: 36.47 (-0.06), LPCN: 7.33 (-0.14), RPRX: 8.98 (-0.26), TEVA: 62.10 (+0.55), LLY: 76.12 (+1.90), ABBV: 60.40 (-0.79), ATRS: 2.67 (-0.02)
3 Stocks Under $10 to Trade for Breakouts: E-House and More
at The Street - Tue Feb 24, 1:15PM CST
These under-$10 stocks are within range of triggering breakout trades.
KEG: 1.83 (+0.16), LPCN: 7.33 (-0.14), EJ: 5.10 (+0.10)
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 13, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CYTK: 7.76 (-0.19), ADHD: 5.54 (-0.15), RCKY: 21.55 (-0.10), LPCN: 7.33 (-0.14), COLM: 59.58 (+0.33)
Lipocine Announces Presentation of LPCN 1107 Clinical Data at the Society for Maternal-Fetal Medicine 35th Annual Meeting
GlobeNewswire - Fri Jan 30, 9:39AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC"
product candidate will be presented at the Society for Maternal-Fetal Medicine 35 Annual Meeting in San Diego, CA. The study was designed to determine the pharmacokinetics and bioavailability of LPCN 1107 relative to an intramuscular (IM) HPC, as well as safety and tolerability, in healthy non-pregnant female volunteers.
LPCN: 7.33 (-0.14)
Lipocine Inc. (Nasdaq: LPCN) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Jan 16, 9:00AM CST
What:
LPCN: 7.33 (-0.14), NDAQ: 50.44 (+0.03)
Lipocine Continues To Generate Positive Data
David Bautz - at Seeking Alpha - Wed Jan 14, 5:45PM CST
LPCN: 7.33 (-0.14)
Lipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women
GlobeNewswire - Mon Jan 12, 8:15AM CST
-- First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant women
LPCN: 7.33 (-0.14)
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 43.60 (-0.65), LPCN: 7.33 (-0.14), EPRS: 9.30 (-0.19), DEPO: 24.12 (-0.75), ASPX: 79.99 (-6.73), BCLI: 4.45 (+0.14), CUR: 2.42 (+0.14)
FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021
GlobeNewswire - Mon Dec 15, 8:05AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Drug Administration ("FDA" that the design of its ongoing pivotal Study of Oral Androgen Replacement ("SOAR" Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300) evaluating efficacy and safety of LPCN 1021 in hypogonadal men with low testosterone ("Low T" is currently acceptable for filing a New Drug Application ("NDA" for the class testosterone replacement therapy ("TRT" labeling. The FDA reiterated the primary efficacy endpoint required for approval being 75% of subjects with a Cavg for serum testosterone in the normal range with the lower bound of the two-sided 95% confidence interval being >65%. Lipocine remains confident that our efficacy results are in line with approval requirements.
LPCN: 7.33 (-0.14)
Lipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 7:07AM CST
Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 2:30 p.m. ET.
LPCN: 7.33 (-0.14)
Lipocine Announces Management Changes
GlobeNewswire - Mon Nov 17, 7:18AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the departures of Dr. Srinivasan Venkateshwaran, Chief Technology Officer and Vice President Research & Development, effective November 14, 2014 and Mr. Gerald Simmons, Chief Business Development Officer, effective November 28, 2014. The Company has an ongoing search for a Chief Medical Officer and a Vice President of Business Development and Commercial.
LPCN: 7.33 (-0.14)
Lipocine axes two execs
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:58PM CST
LPCN: 7.33 (-0.14)
Lipocine Announces Financial and Operational Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 7:42AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as well as recent operational highlights.
LPCN: 7.33 (-0.14)
Lipocine beats by $0.23
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:19AM CST
LPCN: 7.33 (-0.14)
Male Hypogonadism Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Mar 12, 9:32AM CDT
The report "Male Hypogonadism - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Male Hypogonadism. Male hypogonadism is the inability of the testicles to produce testosterone, sperm or both. The symptoms of male hypogonadism includes weakness, muscle and joint aches, increased fat or obesity, enlarged, swollen or tender breasts, reduced facial, body and pubic hair, decreased bone density, bone fractures or osteoporosis, loss of height, sleep apnea, night sweats or hot flushes and fatigue. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/male-hypogon...eport.html .
MRK: 58.58 (+0.37), AUXL: 36.47 (-0.06), LPCN: 7.33 (-0.14), ATRS: 2.67 (-0.02), NVS: 101.68 (+1.81)
Lipocine misses by $0.07
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 8:15AM CDT
LPCN: 7.33 (-0.14)
Lipocine Announces Financial and Operational Results for the Full Year 2014
GlobeNewswire - Wed Mar 11, 8:00AM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2014, as well as recent operational highlights.
LPCN: 7.33 (-0.14)
FDA imposes limits on testosterone drugs and labeling changes to warn of potential heart risks
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 7:23AM CST
ENDP: 92.37 (+0.89), AUXL: 36.47 (-0.06), LPCN: 7.33 (-0.14), RPRX: 8.98 (-0.26), TEVA: 62.10 (+0.55), LLY: 76.12 (+1.90), ABBV: 60.40 (-0.79), ATRS: 2.67 (-0.02)
3 Stocks Under $10 to Trade for Breakouts: E-House and More
at The Street - Tue Feb 24, 1:15PM CST
These under-$10 stocks are within range of triggering breakout trades.
KEG: 1.83 (+0.16), LPCN: 7.33 (-0.14), EJ: 5.10 (+0.10)
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 13, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CYTK: 7.76 (-0.19), ADHD: 5.54 (-0.15), RCKY: 21.55 (-0.10), LPCN: 7.33 (-0.14), COLM: 59.58 (+0.33)
Lipocine Announces Presentation of LPCN 1107 Clinical Data at the Society for Maternal-Fetal Medicine 35th Annual Meeting
GlobeNewswire - Fri Jan 30, 9:39AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC"
product candidate will be presented at the Society for Maternal-Fetal Medicine 35 Annual Meeting in San Diego, CA. The study was designed to determine the pharmacokinetics and bioavailability of LPCN 1107 relative to an intramuscular (IM) HPC, as well as safety and tolerability, in healthy non-pregnant female volunteers. LPCN: 7.33 (-0.14)
Lipocine Inc. (Nasdaq: LPCN) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Jan 16, 9:00AM CST
What:
LPCN: 7.33 (-0.14), NDAQ: 50.44 (+0.03)
Lipocine Continues To Generate Positive Data
David Bautz - at Seeking Alpha - Wed Jan 14, 5:45PM CST
LPCN: 7.33 (-0.14)
Lipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women
GlobeNewswire - Mon Jan 12, 8:15AM CST
-- First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant women
LPCN: 7.33 (-0.14)
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 43.60 (-0.65), LPCN: 7.33 (-0.14), EPRS: 9.30 (-0.19), DEPO: 24.12 (-0.75), ASPX: 79.99 (-6.73), BCLI: 4.45 (+0.14), CUR: 2.42 (+0.14)
FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021
GlobeNewswire - Mon Dec 15, 8:05AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Drug Administration ("FDA"
that the design of its ongoing pivotal Study of Oral Androgen Replacement ("SOAR" Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300) evaluating efficacy and safety of LPCN 1021 in hypogonadal men with low testosterone ("Low T" is currently acceptable for filing a New Drug Application ("NDA" for the class testosterone replacement therapy ("TRT" labeling. The FDA reiterated the primary efficacy endpoint required for approval being 75% of subjects with a Cavg for serum testosterone in the normal range with the lower bound of the two-sided 95% confidence interval being >65%. Lipocine remains confident that our efficacy results are in line with approval requirements. LPCN: 7.33 (-0.14)
Lipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 7:07AM CST
Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 2:30 p.m. ET.
LPCN: 7.33 (-0.14)
Lipocine Announces Management Changes
GlobeNewswire - Mon Nov 17, 7:18AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the departures of Dr. Srinivasan Venkateshwaran, Chief Technology Officer and Vice President Research & Development, effective November 14, 2014 and Mr. Gerald Simmons, Chief Business Development Officer, effective November 28, 2014. The Company has an ongoing search for a Chief Medical Officer and a Vice President of Business Development and Commercial.
LPCN: 7.33 (-0.14)
Lipocine axes two execs
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:58PM CST
LPCN: 7.33 (-0.14)
Lipocine Announces Financial and Operational Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 7:42AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as well as recent operational highlights.
LPCN: 7.33 (-0.14)
Lipocine beats by $0.23
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:19AM CST
LPCN: 7.33 (-0.14)
